Beam Therapeutics Inc. (BEAM)
|52 Week Range||28.04-73.27|
|1y Target Est||-|
|DCF Unlevered||BEAM DCF ->|
|DCF Levered||BEAM LDCF ->|
|Debt / Equity||82.93%||Buy|
Upgrades & Downgrades
Latest BEAM news
Beam Therapeutics: Base Editing Leader With Major Catalyst Next Year
20 May 2023
Beam is a leader in base editing and has strong lab data. It has a huge amount of cash and a major deal with Pfizer.
Beam Therapeutics to Participate in Upcoming May Investor Conferences
17 May 2023
CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that mana...
Cathie Wood Is Loading Up on These 3 Stocks Down 70% or More. Should You?
16 May 2023
Cathie Wood's Ark Invest ETFs added to their positions recently in two biotech stocks and one telehealth stock. All three stocks have plunged over the past couple of years.
Beam Therapeutics to Participate in RBC Capital Markets 2023 Global Healthcare Conference
11 May 2023
CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Gius...
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Tops Revenue Estimates
10 May 2023
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.33 per share versus the Zacks Consensus Estimate of a loss of $1.36. This compares to loss of $1.01 per share a year ago.
7 Best Cathie Wood Stocks for Your May 2023 Buy List
2 May 2023
Cathie Wood invests in speculative stocks that don't always pan out, as 2022 showed. The chief of Ark Investment Management watched her firm outperform in 2021, though last year saw a sharp decelerati...
3 Growth Stocks Cathie Wood Just Bought That Could Be Absolute Game-Changers
2 May 2023
Beam Therapeutics is a pioneer in base editing, an especially promising type of gene editing. CRISPR Therapeutics could soon bring the first CRISPR gene-editing therapy to market.
The 3 Most Promising Gene Editing Stocks to Buy in 2023
28 April 2023
Gene editing stocks are one of the hottest sectors in medicine today. Genes are the foundation of life, and from creating new organisms to curing incurable diseases, the editing of genes can bring rad...
3 Stocks to Watch in April: Is it Time to Buy?
18 April 2023
Heading toward the midway point of the year, the unique dynamics associated with the post-pandemic new normal sets the stage for certain stocks to watch. That is, brewing fundamental and technical fac...
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >